New Results from Phase 1 Study of Zilebesiran Presented at American Heart Association Hypertension Scientific Sessions 2023

10 Sep, 2023 New Results from Phase 1 Study of Zilebesiran Presented at American Heart Association Hypertension Scientific Sessions 2023

New results from Part D of the Phase 1 study of zilebesiran, assessing the safety and pharmacology of sequential doses of zilebesiran in patients with Class II or III obesity, were presented during the American Heart Association Hypertension Scientific Sessions 2023.

Taubel, et al. “Safety and Tolerability of Zilebesiran, an RNAi Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Obese Patients with Hypertension”